Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut Curie
Phase III multicentre, randomized, open-label study comparing early evaluation of the efficacy of chemotherapy by determination of circulating tumour cells versus conventional clinical and radiological evaluation.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women over the age of 18 years.
WHO performance status: 0 to 4.
Metastatic breast cancer.
Progression after 2 lines of chemotherapy with decision to initiate third-line chemotherapy.
Disease evaluable by CTC (CTC-positive before starting chemotherapy).
Histology: lobular or ductal adenocarcinoma.
Information of the patient and signature of the informed consent form by the patient or her legal representative.
You may not be if
Disease not evaluable by CTC (CTC-negative before starting chemotherapy).
History of other potentially metastatic cancer (stage III or IV cancer) different from breast cancer.
Histology other than lobular or ductal adenocarcinoma.
Pregnant woman, women likely to become pregnant or nursing mothers.
Persons deprived of their freedom or under guardianship.
Women unable to comply with the medical follow-up of the study for geographical, social or mental reasons.
Clareo Health | Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast Cancer
